Testing effectiveness (Phase 2)Looking for participantsNCT05937906
What this trial is testing
Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.
Who this might be right for
Non-Small Cell Lung Cancer
Centre Georges Francois Leclerc 24